Your browser doesn't support javascript.
loading
Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group.
Park, Kyung Mi; Yoo, Keon Hee; Kim, Seong Koo; Lee, Jae Wook; Chung, Nack-Gyun; Ju, Hee Young; Koo, Hong Hoe; Lyu, Chuhl Joo; Han, Seung Min; Han, Jung Woo; Choi, Jung Yoon; Hong, Kyung Taek; Kang, Hyoung Jin; Shin, Hee Young; Im, Ho Joon; Koh, Kyung-Nam; Kim, Hyery; Kook, Hoon; Baek, Hee Jo; Kim, Bo Ram; Yang, Eu Jeen; Lim, Jae Young; Park, Eun Sil; Choi, Eun Jin; Park, Sang Kyu; Lee, Jae Min; Shim, Ye Jee; Kim, Ji Yoon; Park, Ji Kyoung; Kong, Seom Gim; Choi, Young Bae; Cho, Bin; Lim, Young Tak.
Affiliation
  • Park KM; Department of Pediatrics, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
  • Yoo KH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kim SK; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Lee JW; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Chung NG; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Ju HY; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Koo HH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Lyu CJ; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
  • Han SM; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
  • Han JW; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
  • Choi JY; Department of Pediatrics, Seoul National University Cancer Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Hong KT; Department of Pediatrics, Seoul National University Cancer Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Kang HJ; Department of Pediatrics, Seoul National University Cancer Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Shin HY; Department of Pediatrics, Seoul National University Cancer Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Im HJ; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Koh KN; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim H; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Kook H; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University medical school, Gwangju, Korea.
  • Baek HJ; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University medical school, Gwangju, Korea.
  • Kim BR; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University medical school, Gwangju, Korea.
  • Yang EJ; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea.
  • Lim JY; Department of Pediatrics, Gyeongsang National University College of Medicine, Jinju, Korea.
  • Park ES; Department of Pediatrics, Gyeongsang National University College of Medicine, Jinju, Korea.
  • Choi EJ; Department of Pediatrics, Daegu Catholic University School of Medicine, Daegu, Korea.
  • Park SK; Department of Pediatrics, University of Ulsan School of Medicine, Ulsan, Korea.
  • Lee JM; Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Korea.
  • Shim YJ; Department of Pediatrics, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.
  • Kim JY; Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Park JK; Department of Pediatrics, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • Kong SG; Department of Pediatrics, Kosin University of Medicine, Busan, Korea.
  • Choi YB; Departments of Pediatrics, Ajou University School of Medicine, Suwon, Korea.
  • Cho B; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Lim YT; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea.
Cancer Res Treat ; 54(1): 269-276, 2022 Jan.
Article in En | MEDLINE | ID: mdl-33887821
ABSTRACT

PURPOSE:

Acute promyelocytic leukemia (APL) is a rare disease in children and there are some different characteristics between children and adult. We aimed to evaluate incidence, clinical characteristics and treatment outcomes of pediatric APL in Korea. MATERIALS AND

METHODS:

Seventy-nine pediatric APL patients diagnosed from January 2009 to December 2016 in 16 tertiary medical centers in Korea were reviewed retrospectively.

RESULTS:

Of 801 acute myeloid leukemia children, 79 (9.9%) were diagnosed with APL. The median age at diagnosis was 10.6 years (range, 1.3 to 18.0). Male and female ratio was 10.93. Thirty patients (38.0%) had white blood cell (WBC) count greater than 10×109/L at diagnosis. All patients received induction therapy consisting of all-trans retinoic acid and chemotherapy. Five patients (6.6%) died during induction chemotherapy and 66 patients (86.8%) achieved complete remission (CR) after induction chemotherapy. The causes of death were three intracranial hemorrhage, one cerebral infarction, and one sepsis. Five patients (7.1%) suffered a relapse during or after maintenance chemotherapy. The estimated 4-year event-free survival and overall survival (OS) rates were 82.1%±4.4%, 89.7%±5.1%, respectively. The 4-year OS was significantly higher in patients with initial WBC < 10×109/L than in those with initial WBC ≥ 10×109/L (p=0.020).

CONCLUSION:

This study showed that the CR rates and survival outcomes in Korean pediatric APL patients were relatively good. The initial WBC count was the most important prognostic factor and most causes of death were related to serious bleeding in the early stage of treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tretinoin / Leukemia, Promyelocytic, Acute / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Asia Language: En Journal: Cancer Res Treat Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tretinoin / Leukemia, Promyelocytic, Acute / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Asia Language: En Journal: Cancer Res Treat Year: 2022 Document type: Article
...